PRESS RELEASES

Date	Title
Apr 29, 2021	Ardelyx Announces Extension of the PDUFA Review Period for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
Apr 16, 2021	Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 14, 2021	Ardelyx Collaboration Partner, Kyowa Kirin, Announces Initiation of Phase 3 Clinical Studies of Tenapanor for Hyperphosphatemia in Japan
Apr 12, 2021	Ardelyx Announces Upcoming Data Presentation at ISN World Congress of Nephrology 2021
Mar 30, 2021	Ardelyx Announces Poster Presentations, Educational Symposium, and Exhibitor Showcase at National Kidney Foundation 2021 Virtual Spring Clinical Meetings
Mar 15, 2021	Ardelyx Appoints Muna Bhanji, R.Ph, to its Board of Directors
Mar 8, 2021	Ardelyx Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights
Feb 17, 2021	Ardelyx to Present at the 10th Annual SVB Leerink Global Healthcare Conference
Nov 23, 2020	Ardelyx to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
Nov 10, 2020	Ardelyx to Present at the Jefferies Virtual London Healthcare Conference

FAQs

Email Alerts

Connect

Bay Area
34175 Ardenwood Boulevard
Fremont, CA 94555

Greater Boston
400 Fifth Avenue, Suite 210
Waltham, MA 02451

Phone: 617.675.ARDX (2739)

Inquiries:
General: info@ardelyx.com
Media: media@ardelyx.com
Investor: investor@ardelyx.com
Business Development: partnering@ardelyx.com